| |
Significant patient populations, top clinical institutions, and ease of regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠ 
|
|
Today's Big NewsOct 18, 2022 |
|
Sino Biological offers rapid mouse monoclonal antibody development service on the Beacon®️ platform and obtains positive clones within 35 days, which accelerates the process of antibody (drug) discovery. Learn more. 
|
|
| By Nick Paul Taylor Roche has taken the scissors to its clinical development pipeline, snipping off phase 2 studies of potential treatments for hepatitis B virus and geographic atrophy in the quarterly cull of its investigational assets. |
|
|
|
By Nick Paul Taylor Eli Lilly has capitalized on the biotech bear market to snap up hearing loss gene therapy player Akouos for $487 million upfront. The deal will give Lilly control of a treatment for a genetic form of hearing loss that is advancing toward a phase 1/2 trial just ahead of Decibel Therapeutics’ rival candidate. |
Sponsored By Cullinan Oncology Cullinan Oncology’s strategic approach to research and development, focusing on modality-agnostic target oncology, positions the company to thrive. |
Sponsored By PathAI TME research is recognized as one of the most promising areas in oncology drug development. AI-powered digital pathology reveals new insights previously hidden by laborious manual pathology methods. |
By James Waldron Salarius Pharmaceuticals has paused enrollment on a phase 1/2 trial of its lead candidate following the death of one patient. |
By Max Bayer J&J has axed an early-stage blood cancer asset amid a shifting of the company's phase 1 roster. It comes as two additional hematological assets were added to the pipeline. |
By Gabrielle Masson Tuberculosis has become increasingly difficult to treat as antibiotic resistance rises and the pipeline of antibiotics in development thins out. Now, Merck & Co. has handed over two preclinical tuberculosis antibiotics to the Bill & Melinda Gates Medical Research Institute to help tackle the problem. |
By James Waldron GSK is paying $70 million to plug into Tempus’ AI-enabled patient data platform with the aim of improving its clinical trial design, speeding up enrollment and identifying new drug targets. |
By Gabrielle Masson As SPAC deals in biotech make a slow comeback, another merger has been penned, this time between Swiss biotech Oculis and European Biotech Acquisition Corp. |
By Helen Floersh The finding opens the door to the use of proline hydroxylase inhibitors to treat beta thalassemia and sickle cell disease. |
By Angus Liu Roche's COVID-19 therapies Ronapreve and Actemra gave the drugmaker a sales boost a year ago amid a surge in infections. But as cases ebb, sales of the drugs are falling sharply. To make things worse, biosimilars continue to wreak havoc on Roche's portfolio as newer drugs disappoint. |
By Andrea Park Theranica is once again asking the FDA to expand its neuromodulation device's approved usage, positioning it as a preventive migraine therapy, in addition to its current use as an acute, on-demand treatment. |
By Paige Minemyer SCAN Health Plan is launching a new plan designed for LGBTQ+ seniors, and executives said they hope the industry takes notice. |
By Kevin Dunleavy Aveo Oncology took a circuitous route on its way to gaining FDA approval for its kidney cancer drug Fotivda. Now with Aveo’s sale to LG Chem, the Korean company hopes to have better luck developing Fotivda and Aveo’s other oncology candidates. On Tuesday, the companies revealed the purchase for what amounts to $566 million. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our latest analysis on the world’s most productive biopharmas. We also discuss Biogen's tumultuous year and who it is considering for a new CEO. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now. 
|
|
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
